Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells

Journal of Immunology

Volumn 174, Issue 2, 2005, Pages 898-906

  Broderick, Lori ^a   Yokota, Sandra J ^a   Reineke, Joshua ^b   Mathiowitz, Edith ^b   Stewart, Carleton C ^c   Barcos, Maurice ^c   Kelleher Jr , Raymond J ^a   Bankert, Richard B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BROWN UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LUNG CANCER; MEMORY CELL; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 11844299075     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.2.898     Document Type: Article

References (44)

1. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420:860.
2. Batra, R. K., Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S. M. Dubinett. 2003. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an IκB kinase-dependent mechanism. Cancer Res. 63:642.
3. Yoo, Y. K., D. S. Heo, K. Hata, D. H. Van Thiel, and T. L. Whiteside. 1990. Tumor-infiltrating lymphocytes from human colon carcinomas: functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 98:259.
4. Ortegel, J. W., E. D. Staren, L. P. Faber, W. H. Warren, and D. P. Braun. 2000. Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunol. Immunother. 48:627.
5. Balkwili, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357:539.
6. Schreiber, H., and D. A. Rowley. 1999. Inflammation and Cancer. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin and R. Snyderman, eds. Lippincott, Willams & Williams, Philadelphia, pp. 1117-1129.
7. Bankert, R. B., N. K. Egilmez, and S. D. Hess. 2001. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22:386.
8. + T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 170:400.
9. Tanaka, T., M. Tsudo, H. Karasuyama, F. Kitamura, T. Kono, M. Hatakeyama, T. Taniguchi, and M. Miyasaka. 1991. A novel monoclonal antibody against murine IL-2 receptor β-chain: characterization of receptor expression in normal lymphoid cells and EL-4 cells. J. Immunol. 147:2222.
10. Mathiowitz, E., J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chickering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S. Montgomery, M. Bassett, et al. 1997. Biologically erodable microsphere as potential oral drug delivery system. Nature 386:410.
11. Iwanuma, Y., F. A. Chen, N. K. Egilmez, H. Takita, and R. B. Bankert. 1997. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 57:2937.
12. Hess, S. D., N. K. Egilmez, J. Shiroko, and R. B. Bankert. 2001. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Ther. 8:371.
13. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919.
14. Gumperz, J. E., S. Miyake, T. Yamamura, and M. B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625.
15. Dzionek, A., A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D. W. Buck, and J. Schmitz. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165:6037.
16. Dzionek, A., Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Gunther, I. Johnston, A. Lanzavecchia, T. Nagasaka, et al. 2001. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194:1823.
17. Campbell, J. J., K. E. Murphy, E. J. Kunkel, C. E. Brightling, D. Soler, Z. Shen, J. Boisvert, H. B. Greenberg, M. A. Vierra, S. B. Goodman, et al. 2001. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166:877.
18. Roman, E., E. Miller, A. Harmsen, J. Wiley, U. H. Von Andrian, G. Huston, and S. L. Swain. 2002. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J. Exp. Med. 196:957.
19. + CTLs ex vivo. J. Immmol. 168:5954.
20. + lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur. J. Immunol. 22:993.
21. Hintzen, R. Q., R. De Jong, S. M. Lens, M. Brouwer, P. Baars, and R. A. van Lier. 1993. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151:2426.
22. Egilmez, N. K., Y. S. Jong, M. S. Sabel, J. S. Jacob, E. Mathiowitz, and R. B. Bankert. 2000. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60:3832.
23. + effector T cells mediate indirect interleukin-12-and interferon-γ-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 62:2611.
24. Loza, M. J., L. S. Metelitsa, and B. Perussia. 2002. NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur. J. Immunol. 32:3453.
25. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413.
26. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.
27. Park, S. H., T. Kyin, A. Bendelac, and C. Carnaud. 2003. The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol. 170:1197.
28. Smyth, M. J., M. Taniguchi, and S. E. Street. 2000. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165:2665.
29. Kim, C. H., E. C. Butcher, and B. Johnston. 2002. Distinct subsets of human Vα24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 23:516.
30. Thomas, S. Y., R. Hou, J. E. Boyson, T. K. Means, C. Hess, D. P. Olson, J. L. Strominger, M. B. Brenner, J. E. Gumperz, S. B. Wilson, et al. 2003. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171:2571.
31. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
32. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2:123.
33. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521.
34. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835.
35. + T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166:1813.
36. + T cells after infection. Nat. Immunol. 3:619.
37. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793.
38. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30:1410.
39. Choi, S. H., E. J. Chung, D. Y. Whang, S. S. Lee, Y. S. Jang, and C. W. Kim. 1998. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol. Immunother. 45:299.
40. Matsuda, M., M. Petersson, R. Lenkei, J. L. Taupin, I. Magnusson, H. Mellstedt, P. Anderson, and R. Kiessling. 1995. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61:765.
41. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.
42. Krishnan, S., V. G. Warke, M. P. Nambiar, H. K. Wong, G. C. Tsokos, and D. L. Farber. 2001. Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3ζ expression. Blood 97:3851.
43. Yu, P., Y. Lee, W. Liu, R. K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y. X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141.
44. Dong, H., and L. Chen. 2003. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 81:281.